Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of APN311 (ch14.18/CHO) continuous infusion in refractory or relapsed neuroblastoma
2014-000588-42Phase 2Completed
- Sponsor
- Universitätsklinikum Greifswald
- Start
- Jul 2014
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Dinutuximab beta in neuroblastoma, sponsored by Universitätsklinikum Greifswald. Primary endpoint: Primary anti-tumor activity endpoint. Started Jul 2014; status: completed.
02
Drugs
Dinutuximab beta
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on 2014-000588-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000588-42.